Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Maingon

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2021
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancersR Palich, M Veyri, A Vozy, et al.
Cardiovascular Drugs and Therapy|April 13, 2001
Intravascular radiation and stenting: absence of efficacy on intimal proliferation in a rabbit modelD Busseuil, M Zeller, Y Cottin, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 1998
Preoperative radiotherapy and surgery for endometrial carcinoma: prognostic significance of the sterilization of the specimenP Maingon, L Arnould, V Magnin, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 29, 2019
[From bunker construction to patient treatment: quality controls applied to modern radiotherapy techniques]G Klausner, E Blais, C Martin, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 10, 2017
[Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy]E Blais, B Pichon, A Mampuya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO studyB Chauffert, F Mornex, F Bonnetain, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2000
Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary resultsP Bey, C Carrie, V Beckendorf, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 30, 2020
Dose distribution of the brain tissue associated with cognitive functions in high-grade glioma patientsJ Jacob, E Clausse, M A Benadjaoud, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2009
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)O Matzinger, F Roelofsen, L Mineur, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 15, 2011
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]M Barhoumi, F Mornex, F Bonnetain, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2021
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancersR Palich, M Veyri, A Vozy, et al.
Cardiovascular Drugs and Therapy|April 13, 2001
Intravascular radiation and stenting: absence of efficacy on intimal proliferation in a rabbit modelD Busseuil, M Zeller, Y Cottin, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 1998
Preoperative radiotherapy and surgery for endometrial carcinoma: prognostic significance of the sterilization of the specimenP Maingon, L Arnould, V Magnin, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 29, 2019
[From bunker construction to patient treatment: quality controls applied to modern radiotherapy techniques]G Klausner, E Blais, C Martin, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 10, 2017
[Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy]E Blais, B Pichon, A Mampuya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO studyB Chauffert, F Mornex, F Bonnetain, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2000
Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary resultsP Bey, C Carrie, V Beckendorf, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 30, 2020
Dose distribution of the brain tissue associated with cognitive functions in high-grade glioma patientsJ Jacob, E Clausse, M A Benadjaoud, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2009
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)O Matzinger, F Roelofsen, L Mineur, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 15, 2011
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]M Barhoumi, F Mornex, F Bonnetain, et al.
Pageof 16